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LPI: labile plasma iron 
LIC: liver iron content 
MRI: magnetic resonance imaging 
SNP: single nucleotide polymorphism 
TFsat: serum transferrin saturation
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Abstract 
As our understanding of iron metabolism improves through the more accurate description of 
iron metabolism actors, new causes of iron overload are identified. We, here, report 16 cases 
of hereditary hypotransferrinemia related to 4 previously undescribed TF (transferrin) 
mutations (p.Val221Gly, p.Arg609Trp, p.Glu370Lys, p.Tyr533X and p.Cys421Arg). We 
show that, besides increasing serum transferrin saturation without iron overload, 
hypotransferrinemia, when associated to mutations in HFE or HAMP or to acquired factors, 
can lead to clinically relevant iron burden. These cases emphasize the usefulness of serum 
transferrin determination in the diagnostic evaluation of iron overload and the importance for 
clinicians to be aware of this syndrome. 
 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
Introduction 
Understanding of iron metabolism has made important progress as new genes and their roles 
have been described in iron metabolism [1]. Mutations of those genes are searched for as part 
of the diagnosis of primary iron overload [2]. 
The TF gene encodes transferrin which is the iron carrier protein in bloodstream [3].  In the 
clinical setting, serum transferrin saturation (TFsat) is a pivotal parameter as it represents the 
biologically available iron, and elevated transferrin saturation is highly suggestive of iron 
overload. 
Atransferrinemia is characterized by undetectable serum transferrin, liver iron overload, 
severe anaemia, and juvenile onset [4-8]. In accordance with its autosomal recessive 
transmission, heterozygous relatives showed halved transferrin level but normal 
haematological parameters. However, data regarding their iron metabolism parameters 
remains poorly documented. 
Genome-wide association studies showed that TF variants partly explained variations in 
serum transferrin levels of asymptomatic subjects, and may affect TFsat and serum ferritin 
[9]. Moreover, in vivo study showed that serum transferrin may have a direct role in hepcidin 
expression [10]. This suggests that serum transferrin level related to TF mutations could 
impact serum transferrin saturation levels and iron metabolism. 
Here, we report, in seven families, 16 cases of hypotransferrinemia related to 4 previously 
undescribed TF mutations. We show that, beside increasing TFsat without iron overload, 
hypotransferrinemia in association to mutations in HFE or HAMP can lead to clinically 
relevant iron overload. 
Materials & Methods 
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TF mutations were screened following the identification of hypotransferrinemia (serum 
transferrin <1.5g/L) in 7 patients referred for suspected iron overload.  
In all patients, conditions able to decrease transferrin concentration such as malnutrition, 
protein malabsorption, hepatocellular failure, and urinary protein losses were ruled out. 
The coding region and intronic flanking sequences of the TF gene (RefSeq NM_001063.3) 
were sequenced using the BigDye terminator cycle sequencing kit on a 3130 Genetic 
Analyser (Applied Biosystems). 
The coding sequences of HFE, HJV, HAMP, TFR2, SLC40A1, CP, FTL, FH1, were analysed 
by Next Generation Sequencing (NGS) with the Ion Torrent Ampliseq technology on a 
Personal Genome Machine. 
The potential consequences of TF mutations were assessed using the algorithm SIFT 
(http://sift.jcvi.org/) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/bgi.shtml). 
Serum hepcidin levels were determined using enzyme immunoassay (Peninsula Laboratories, 
Bachem, San Carlos USA). Serum hepcidin/ferritin ratios were calculated as follows: (serum 
hepcidin/serum ferritin) X100. Non-transferrin bound iron (NTBI) and Labile Plasma Iron 
(LPI) were determined as previously described [11]. 
Family screening was advised for probands carrying mutation(s). Written informed consent 
was obtained from each patient and the study was performed in accordance with the 
Declaration of Helsinki and with the French regulation on medical genetic diagnosis. 
Results 
Table I describes the clinical characteristics of the patients. 
Patient 1 (proband of family 1, Figure 1) had the p.Val221Gly (c.662T>G) TF mutation and 
the p.Gly71Asp (c.212G>A) HAMP mutation. He had increased TFsat and iron overload. 
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Interestingly, one brother (patient 4) was diagnosed with unexplained iron overload 10 years 
earlier (serum ferritin was 2500 µg/L (N<300µg/L) at diagnosis; he had weekly phlebotomies 
for several months and maintenance phlebotomy since then). Patient 4 harboured both 
mutations (p.Val221Gly in TF, p.Gly71Asp in HAMP). Moreover, he was a compound 
heterozygote for the p.Cys282Tyr and p.His63Asp mutations in HFE. Family 1 pedigree 
suggests a good segregation between mutation in both TF and HAMP and the development of 
iron overload. This phenotype could even be more severe when associated with HFE 
mutation. Relatives with TF mutation and HFE compound heterozygosity only, did not 
develop iron overload (Patients 3 and 5), neither did relatives with the sole HAMP mutation 
(Figure 1: patients III.1 and III.3). 
Patient 6, and patients 7, 8, 9 belonged to two unrelated families but had the same p.Tyr533X 
(c.1599_1600del) mutation. Patient 6 had increased TFsat and iron overload. He underwent 
venesections and 6.2g of iron were removed. Despite having the same serum transferrin levels 
as patient 6, patients 7, 8 and 9 showed no signs of iron overload. Of note, patient 6 had also 
the previously described SNP rs1799852 (c.739C>T, p.Leu247Leu)[9]. 
Patients 10 and 11 had the undescribed p.Cys421Arg (c.1261T>C) mutation. Both had slight 
iron overload. 
Patient 12 had the undescribed splicing mutation c.1623-1 G>T which could induce a loss of 
exon 14, and the polymorphism p.Leu247Leu. This mutation was absent in his sister who had 
normal serum transferrin and normal iron parameters. 
Patient 13 had the p.Tyr445Cys (c.1334A>G) and the previously described p.Arg609Trp 
(c.1825C>T) mutation [8]. He had significant iron overload. However, he also had overt 
alcoholic liver disease and metabolic syndrome. His sister presented the p.Tyr445Cys 
polymorphism only and had normal serum transferrin and iron parameters. His daughter 
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(patient 14) had the p.Arg609Trp mutation only and presented slightly decreased serum 
transferrin. 
Patients 15 and 16 had the p.Glu370Lys (c.1108G>A) mutation. Patient 15 was heterozygous 
for the p.Cys282Tyr HFE mutation and presented slight iron overload, while patient 16 had 
increased transferrin saturation but barely increased serum ferritin. 
According to Polyphen-2, TF mutations p.Cys421Arg, p.Tyr445Cys, p.Arg609Trp, 
p.Glu370Lys and p.Val221Gly were probably damaging. According to SIFT, TF mutations 
p.Tyr445Cys, p.Arg609Trp, and p.Val221Gly were deleterious, while TF mutations 
p.Cys421Arg and p.Glu370Lys were tolerated. The HAMP p.Gly71Asp mutation was 
predicted tolerated or benign according to SIFT and Polypehn-2, respectively. 
No additional mutations were found in the other sequenced genes. Of note, only patient 2 
presented with anaemia which was likely related to her haematological malignancy. 
Discussion 
To our knowledge, this is the first report describing the consequences of genetic 
hypotransferrinemia on iron metabolism. We show that heterozygous mutations in TF can 
lead to low serum transferrin levels and increased transferrin saturation without affecting 
erythropoiesis. Moreover, we show that low transferrin levels when associated to genetic or 
acquired modifiers can lead to iron overload. Overall, our data emphasize the usefulness of 
serum transferrin level assessment in the diagnosis evaluation of iron overload. 
Interestingly, levels of serum transferrin may be different between patients despite carrying 
identical mutations, suggesting additional, yet unidentified, regulatory factors. However, 
despite the low levels of functional protein, haematopoiesis was normal confirming 
haplosufficiency of the TF gene. 
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Contrary to haematopoiesis, our results shows that iron metabolism regulation was impaired 
in some patients, but serum transferrin was not predictive of iron overload since some patients 
had both normal serum ferritin values and TFsat. It is noteworthy that TFsat was not strictly 
correlated to the protein level, suggesting an adaptive mechanism which accordingly would 
lower serum iron levels. 
NTBI and LPI, which could have been raised in this situation of high TFsat, were normal. 
This may be partly related to the relatively moderate increase of TFsat in most cases (only 3 
had Tfsat over 75%) but suggests also that in case of low serum transferrin levels, an adaptive 
mechanism regulates iron release into the bloodstream to maintain a close to normal 
transferrin saturation. However, in the presence of genetic or acquired factors, this mechanism 
could be overwhelmed. The normal serum hepcidin and serum hepcidin/ferritin ratio suggest 
that this mechanism is not related to hepcidin secretion. 
Most of the patients were free of iron overload. Whenever significant iron overload was found 
it was not clearly correlated with serum transferrin levels or transferrin saturation levels. This 
may be related to the absence of NTBI and suggests that hypotransferrinemia is only a factor 
of susceptibility to iron overload, which would be only expressed in the presence of acquired 
or genetic factors. 
Family 1 was especially informative regarding the impact of associated genetic factor. The 
pedigree clearly showed that simultaneous mutations in TF and HAMP lead to iron overload 
in patients without acquired factors. The p.Gly71Asp mutation in HAMP has already been 
described although its relevance remains controversial [12, 13]. However, in our subject, we 
excluded mutations in other genes involved in iron metabolism, and no acquired factors were 
associated, which strongly suggests the pathological role of the p.Gly71Asp mutation. The 
impact of HFE compound heterozygosity is more difficult to assess. Its association with the 
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sole TF mutation did not result in iron overload while, when associated with both TF and 
HAMP mutations, a more severe disease may develop. 
Otherwise, gender may have been another factor leading to the expression of iron overload in 
our subjects. It is noteworthy that all men had high serum ferritin levels, which is in line with 
the well-known overexpression of HFE haemochromatosis in males and with the recent 
finding of hepcidin regulation by testosterone [14]. 
In conclusion, we suggest that heterozygous TF mutation leads to haplosufficiency regarding 
haematopoiesis but induces susceptibility to iron overload due to haploinsufficiency regarding 
a still unidentified impact on iron metabolism regulation. On a practical point of view, 
considering not only transferrin saturation but also serum transferrin level must be the rule 
when facing with putative iron overload. 
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Legends 
Figure 1: Pedigree of family 1 
Tf: serum transferrin (N:2-3,8 g/L). Frt: serum ferritin (µg/L, N<200 in women and <300 in 
men). Sat: serum transferrin saturation (N<45%). 
Arrow indicates the index case. 
 
Table 1 Clinical and biological characteristics of patients 
F: family number, P: proband (index case), N: patient number 
TF: serum transferrin (g/l, N: 2-3,8), Iron : serum iron (μmol/l, N:12,5-25), TFsat: serum 
transferrin saturation (%, N <45), Ferritin: serum ferritin (µg/L, N<200 in women and <300 in 
men), Hepcidin: serum hepcidin level (nmol/l, N:4-30), hepcidin ferritin ratio (N:4-30), LIC: 
Liver Iron Content determined by magnetic resonance imaging (µmol/g, N<40). NTBI: Non 
transferrin bound iron (N<0,5 µmol/L). LPI: Labile Plasma Iron (N<0,5 µmol/L). 
* denote value after phlebotomies, initial values are in parentheses. 
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F P N Sex Age Comorbidity TF Iron 
TF 
Sat 
Ferritin Hepcidin 
Hepcidin 
/ferritin 
Ratio 
NTBI 
/ LPI 
LIC Transferrin HFE HAMP 
1 
P 1 M 67 BMI 25 1.1 14.7 53 611 22.2 4 <0,5 170 p.[Val221Gly];[=] p.[=];[=] p.[Gly71Asp];[=] 
 2 F 76 
High grade 
Non Hodgkin 
Lymphoma 
0.95 10.4 43 1527 22.5 2.1   p.[Val221Gly];[=] p.[Cys282Tyr];[=] p.[=];[=] 
 3 F 64  1 16 64 325 16.4 5 <0,5  p.[Val221Gly];[=] p.[His63Asp];[Cys282Tyr] p.[=];[=] 
 4 M 73 
bloodletting 
since 2004 
1.2 15.5 
52* 
(95) 
96* 
(2500) 
2.1 2.2   p.[Val221Gly];[=] p.[His63Asp];[Cys282Tyr] p.[Gly71Asp];[=] 
 5 M 74  1.21 17.5 58 90     p.[Val221Gly];[=] p.[His63Asp];[Cys282Tyr] p.[=];[=] 
2 P 6 M 52  1.3 17.9 55 886    170 p.[Tyr533X];[=] p.[=];[=] p.[=];[=] 
3 
P 7 F 70  1.07 20.4 76 143     p.[Tyr533X];[=] p.[His63Asp];[=] p.[=];[=] 
 8 F 47  1.3 25 75 154     p.[Tyr533X];[=] p.[His63Asp];[Cys282Tyr] p.[=];[=] 
 9 F 61  1.5 20.6 54.9 44     p.[Tyr533X];[=] p.[His63Asp];[=] p.[=];[=] 
4 
P 10 M 39 BMI 26 1.3 22.4 68 665 26.6 4.3 <0,5 75 p.[Cys421Arg];[=] p.[=];[=] p.[=];[=] 
 11 M 51  1.25 9.8 31.7 934 28.3 3.1 <0,5 70 p.[Cys421Arg];[=] p.[=];[=] p.[=];[=] 
5 P 12 F 70 
HTA, 
Dyslipidemia, 
BMI 32, 
regular blood 
donation 
1.3 10.6 32 542 39 7.7 <0,5  
c.1623-1G>T 
(splicing mutation) 
p.[=];[=] p.[=];[=] 
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6 
P 13 M 63 
Dyslipidemia, 
diabetes, 
alcoholic liver 
disease 
0.9 12.4 55 2088    270 
p.[Arg609Trp]; 
[p.Tyr445Cys] 
p.[=];[=] p.[=];[=] 
 14 F 28  1.7 16.6 39.7 258     p.[Arg609Trp];[=] p.[Cys282Tyr];[=] p.[=];[=] 
7 
P 15 M 51  1.2 17.6 58 700    90 p.[Glu370Lys];[=] p.[Cys282Tyr];[=] p.[=];[=] 
 16 F 49 Dyslipidemia 1.12 22 79 288     p.[Glu370Lys];[=] p.[=];[=] p.[=];[=] 
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